<p>Bar diagram for (<b>A</b>) dose dependent effect of rosuvastatin (2.5–40 µM) in wound regeneration by VSMC treated without/with agLDL 8 hours after wounding. P<0.01 (Kruskal-Wallis test) for rosuvastatin dose-response effect and P<0.001 for simvastatin effect (Man-Whitney test) vs agLDL-group. (<b>B and C</b>) VSMC were treated without or with rosuvastatin (10 µM) since 2 hours before (2 h-pre LDL) or 8 hours after (8 h-post LDL) adding agLDL to the cell culture medium. <b>B:</b> staining with Herxheimer reagent (Sudan III and Sudan IV) (red colour) as a control for intra-cellular accumulation of lipids. Ø refers to agLDL-VSMC non treated with rosuvastatin. <b>C:</b> Results shown as mean±SEM (% of wounded area at time 0) refer % of the ...
<p>Data are median (25–75% interquartile range).</p><p><sup>1</sup> Difference in response between r...
<p>In order to monitor the reversibility of lovastatin or triparanol treatment on the G1 arrest of c...
<p>(<b>A</b>) Wound healing assay. <i>Left panel</i> shows quantitative analysis of the percentage o...
<p>agLDL-VSMC incubated with rosuvastatin in absence/presence of inhibitors for ROCK (Y27632) or MLC...
<p>Confocal microscopy for RhoA antigen labelling (green) in migrating cells (FCS-stimulated), 4 hou...
<p>(<b>A</b>) Antigen (total RhoA) and active RhoA (RhoA-GTP) levels in total cell lysates and cytos...
<p>(<b>A</b>) Representative 2-DE gel of the cytoskeleton/membrane fraction. Arrows show spots ident...
<p>(A) After treating EPCs with 2.5–10 μM atorvastatin or rosuvastatin for 24 hours, an <i>in vitro<...
<p>(A) HCT116/vector and HCT116/MACC1 cells were treated with 5 μM lovastatin for 24 h, and migratio...
<p>VSMC incubated without/with agLDL, in the absence/presence of rosuvastatin analyzed by western bl...
<p>Dose response curves for (A) MCF-7 RFP, (B) MDA-MB-231 RFP, (C) MDA-MB-231 RFP/Ecad, (D) DU-145 R...
Growing human atherosclerotic plaques show a progressive loss of vascular smooth muscle cells (VSMC)...
<div><p>Growing human atherosclerotic plaques show a progressive loss of vascular smooth muscle cell...
The time dependence of lovastatin (LST) induced effects on proliferation and apoptosis were determin...
<p>The cells were pre-incubated by CS905 (100 nM), SP600125 (20 µM), and SB203580 (20 µM) for 20 min...
<p>Data are median (25–75% interquartile range).</p><p><sup>1</sup> Difference in response between r...
<p>In order to monitor the reversibility of lovastatin or triparanol treatment on the G1 arrest of c...
<p>(<b>A</b>) Wound healing assay. <i>Left panel</i> shows quantitative analysis of the percentage o...
<p>agLDL-VSMC incubated with rosuvastatin in absence/presence of inhibitors for ROCK (Y27632) or MLC...
<p>Confocal microscopy for RhoA antigen labelling (green) in migrating cells (FCS-stimulated), 4 hou...
<p>(<b>A</b>) Antigen (total RhoA) and active RhoA (RhoA-GTP) levels in total cell lysates and cytos...
<p>(<b>A</b>) Representative 2-DE gel of the cytoskeleton/membrane fraction. Arrows show spots ident...
<p>(A) After treating EPCs with 2.5–10 μM atorvastatin or rosuvastatin for 24 hours, an <i>in vitro<...
<p>(A) HCT116/vector and HCT116/MACC1 cells were treated with 5 μM lovastatin for 24 h, and migratio...
<p>VSMC incubated without/with agLDL, in the absence/presence of rosuvastatin analyzed by western bl...
<p>Dose response curves for (A) MCF-7 RFP, (B) MDA-MB-231 RFP, (C) MDA-MB-231 RFP/Ecad, (D) DU-145 R...
Growing human atherosclerotic plaques show a progressive loss of vascular smooth muscle cells (VSMC)...
<div><p>Growing human atherosclerotic plaques show a progressive loss of vascular smooth muscle cell...
The time dependence of lovastatin (LST) induced effects on proliferation and apoptosis were determin...
<p>The cells were pre-incubated by CS905 (100 nM), SP600125 (20 µM), and SB203580 (20 µM) for 20 min...
<p>Data are median (25–75% interquartile range).</p><p><sup>1</sup> Difference in response between r...
<p>In order to monitor the reversibility of lovastatin or triparanol treatment on the G1 arrest of c...
<p>(<b>A</b>) Wound healing assay. <i>Left panel</i> shows quantitative analysis of the percentage o...